NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Vericel Corporation VCEL
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$276.3M
▲ 16.5% vs FY2024
EPS · FY25
$0.32
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
5.1%
Net margin · FY25
6.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 276.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
6 cents of every revenue dollar became profit this year.
Per share
USD 0.32
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
5.1%
Return on equity, FY2025
ROE
Operating margin4.0%
Net margin6.0%
Return on assets3.6%
Each USD of equity produced 5 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+17.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.1%
+17.3%
+18.4%
Net income
+42.0%
EPS, diluted
+39.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+10.5%
Change, 10 years+112.8%
The share count grew 11% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 488.0M
total assets, end of FY2025
Total assetsUSD 488.0M
EquityUSD 354.6M
CashUSD 100.1M
Current ratio5.03×
Equity funds 73% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
Revenue $B
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Net income $B
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.32
0.20
−0.07
−0.35
−0.16
0.06
−0.22
−0.20
−0.52
−1.18
−0.97
−2.23
−6.95
−16.25
−10.18
−0.59
−0.90
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
5.1
4.0
−1.5
−9.2
−4.9
2.3
−9.1
−13.0
−73.2
−83.5
−56.6
−100.8
·
·
·
−92.3
−95.9
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.03
0.02
0.02
0.00
0.00
0.04
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed